Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 13 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

8%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

9 recruiting

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 1
1(25.0%)
Phase 4
1(25.0%)
4Total
N/A(2)
Phase 1(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT07495111Not ApplicableRecruiting

Prophylactic PS Placement to Prevent Pancreatitis After Endoscopic Transpapillary GPC for Cholelithiasis With Concomitant Choledocholithiasis

Role: collaborator

NCT07413068Recruiting

Treatment Outcomes and Complications of Three Therapeutic Approaches for Concomitant Choledocholithiasis and Cholecystolithiasis

Role: collaborator

NCT07379268Recruiting

Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.

Role: collaborator

NCT07379255Recruiting

Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.

Role: collaborator

NCT07379281Recruiting

Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology

Role: collaborator

NCT05993429Completed

Diagnostic Efficacy of EUS-FNA/B Versus ERCP With or Without POCS-TB in Patients With Suspected Hilar Cholangiocarcinoma

Role: collaborator

NCT05737953Recruiting

Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

Role: collaborator

NCT05984511Not ApplicableRecruiting

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Role: collaborator

NCT06662071Recruiting

A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology

Role: collaborator

NCT05794425Phase 1Recruiting

Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders

Role: collaborator

NCT05905744Unknown

"eyeMax Insight" Cholangioscopy for Unexplained Bile Duct Stenosis

Role: collaborator

NCT04901117Phase 4Unknown

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days

Role: collaborator

NCT03510832Unknown

Evaluation of Antithrombotic STrategies in STEMI Patients in China

Role: collaborator

All 13 trials loaded